Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2B, Randomized, Double Blind, Placebo-Controlled, Multicenter Study To Compare 6 Dose Regimens Of CP-690,550 Vs. Placebo, Each Combined With Methotrexate, Administered For 6 Months In The Treatment Of Subjects With Active Rheumatoid Arthritis Who Have Had An Inadequate Response To Methotrexate Alone
Brief Summary: The purpose of this study is to determine the effectiveness and safety, over 6 months, of 6 dose regimens of CP-690,550, combined with methotrexate, for the treatment of adults with active rheumatoid arthritis.


Options:
A: Arm Label: Abatacept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept | Arm Label: Adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Adalimumab | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Adalimumab
B: Arm Label: CNTO 148 50 mg + methotrexate; Type: EXPERIMENTAL; Interventions: Drug: CNTO 148, Drug: Methotrexate (MTX) | Arm Label: CNTO 148 100 mg + methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate (MTX) | Arm Label: Placebo + methotrexate; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Methotrexate (MTX) | Intervention Type: DRUG; Name: CNTO 148; Assigned to Arm(s): CNTO 148 50 mg + methotrexate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + methotrexate | Intervention Type: DRUG; Name: Methotrexate (MTX); Assigned to Arm(s): CNTO 148 100 mg + methotrexate, CNTO 148 50 mg + methotrexate, Placebo + methotrexate
C: Arm Label: CP 690,550 1 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: CP 690,550 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: CP 690,550 15 mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: CP 690,550 3 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: CP 690,550 5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: CP-690,550 20 mg QD; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): CP 690,550 1 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): CP 690,550 10 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): CP 690,550 15 mg | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): CP 690,550 3 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): CP 690,550 5 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): CP-690,550 20 mg QD | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Phase 1 Etanercept + methotrexate; Type: EXPERIMENTAL; Interventions: Biological: Phase 1: Etanercept, Drug: Phase 1: Methotrexate, Drug: Phase 2: Optional ETN, SSZ, HCQ, MTX | Arm Label: Phase 1 Conventional DMARD (SSZ or HCQ) + MTX; Type: ACTIVE_COMPARATOR; Interventions: Drug: Phase 1: Methotrexate, Drug: Phase 1: Conventiaonal DMARD | Intervention Type: BIOLOGICAL; Name: Phase 1: Etanercept; Assigned to Arm(s): Phase 1 Etanercept + methotrexate | Intervention Type: DRUG; Name: Phase 1: Methotrexate; Assigned to Arm(s): Phase 1 Etanercept + methotrexate | Intervention Type: DRUG; Name: Phase 2: Optional ETN, SSZ, HCQ, MTX; Assigned to Arm(s): Phase 1 Etanercept + methotrexate | Intervention Type: DRUG; Name: Phase 1: Methotrexate; Assigned to Arm(s): Phase 1 Conventional DMARD (SSZ or HCQ) + MTX | Intervention Type: DRUG; Name: Phase 1: Conventiaonal DMARD; Assigned to Arm(s): Phase 1 Conventional DMARD (SSZ or HCQ) + MTX

Answer: C